{"name":"Cala Health, Inc.","slug":"cala","ticker":"Private","exchange":"Private","domain":"calahealth.com","description":"Cala Health, Inc. is a private MedTech company focused on bioelectronic medicine. The company is developing innovative therapies for neurological disorders. Cala Health's key products include its proprietary bioelectronic devices. The company is positioned to capitalize on the growing demand for bioelectronic treatments.","hq":"Burlingame, CA","founded":0,"employees":"","ceo":"Renee Ryan","sector":"MedTech / Bioelectronic Medicine","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$250M last valuation)","metrics":{"revenue":20000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-02-24","type":"regulatory","headline":"Cala Health Announces FDA Clearance for its Cala Trio System","summary":"Cala Health received FDA clearance for its Cala Trio System, a non-invasive bioelectronic device for the treatment of essential tremor.","drugName":"Cala Trio System","sentiment":"positive"},{"date":"2021-06-15","type":"deal","headline":"Cala Health Raises $100 Million in Series C Funding","summary":"Cala Health raised $100 million in Series C funding to support the development of its bioelectronic therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQX18xdzNVTGZMY243QkdCd3NBYjY1QjlFeDB4aFE2ek1zdlVjemFEQ2Y1X2RDd0Z2TGs1ZjBzY3dmWjNWNzRqMFFmTXp1MEY3VjlzaHdJM2hnZ2hIeUtKUC1pTUJWTThCR01MSmJlSV9HRU1adWNyank0VzBXTUpZQ1JhNlJudw?oc=5","date":"2025-06-04","type":"pipeline","source":"The Healthcare Technology Report.","summary":"The Top 25 MedTech Companies of 2025 - The Healthcare Technology Report.","headline":"The Top 25 MedTech Companies of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPazNVTUhETjRtVWNuUVIyQThRclFCN2FTdnBDRHdTa1pveUVMVGlvRnN0bklKTDB5VXhBbjZ5bDk4a1NuSmV6bzZNZmtoZEhydzVRdktQMFphZnA4YUprMXdjVG12TEY1ZEFaam00YXF0YXY2ZVMzMWFtMHdIMmMzQnN5VEMzaEdVNUl4QUI5bVRtVER6cDFwQWln?oc=5","date":"2022-01-11","type":"pipeline","source":"The Healthcare Technology Report.","summary":"The Top 25 Women Leaders in Medical Devices of 2022 - The Healthcare Technology Report.","headline":"The Top 25 Women Leaders in Medical Devices of 2022","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-05-04","type":"pipeline","source":"CrossRiverWatch","summary":"Calabar Pharmaceutical Company; Ayade’s Strategic Investment For Reducing Nigeria’s Dependence On Imported Pharmaceutical Products BY EMMANUEL ETIM - CrossRiverWatch","headline":"Calabar Pharmaceutical Company; Ayade’s Strategic Investment For Reducing Nigeria’s Dependence On Imported Pharmaceutica","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2017-02-21","type":"pipeline","source":"CrossRiverWatch","summary":"Ayade Sets May 2017 Deadline For Commissioning Of Calabar Pharmaceutical Company - CrossRiverWatch","headline":"Ayade Sets May 2017 Deadline For Commissioning Of Calabar Pharmaceutical Company","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Abbott Laboratories","Boston Scientific Corporation","Medtronic plc"],"therapeuticFocus":["Neurological Disorders","Bioelectronic Medicine"],"financials":null,"yahoo":null}